Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21616261 | 0.91 | ALDH1A1 (0.48) | ALDH1A1MAPTHSD17B10KDM4EMAPK1 | |
| SCHEMBL11652171 | 0.89 | ALDH1A1 (0.50) | ALDH1A1MAPTHSD17B10KDM4EMAPK1 | |
| SCHEMBL11653686 | 0.87 | ALDH1A1 (0.53) | ALDH1A1MAPTHSD17B10KDM4EMAPK1 | |
| SCHEMBL148285 | 0.87 | MAPT (0.53) | ALDH1A1MAPTHSD17B10KDM4EMAPK1 | |
| SCHEMBL29358090 | 0.87 | MAPT (0.53) | ALDH1A1MAPTHSD17B10KDM4EMAPK1 | |
| SCHEMBL13324326 | 0.86 | KDM4E (0.49) | ALDH1A1MAPTHSD17B10KDM4EMAPK1 | |
| Hydrochloric Acid SCHEMBL3341943 | 0.85 | MAPT (0.52) | ALDH1A1MAPTHSD17B10KDM4EMAPK1 | |
| Hydrochloric Acid SCHEMBL29358790 | 0.85 | MAPT (0.52) | ALDH1A1MAPTHSD17B10KDM4EMAPK1 | |
| Hydrochloric Acid SCHEMBL10362702 | 0.85 | MAPT (0.52) | ALDH1A1MAPTHSD17B10KDM4EMAPK1 | |
| SCHEMBL17735425 | 0.83 | MAPT (0.50) | ALDH1A1MAPTHSD17B10KDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10251827-B2 | Oxidation dyeing process using a composition comprising a monoaminobenzene and a metal catalyst | L'OREAL (FR) | 2019-04-09 | — | — | US | disclosed |
| US-20160128922-A1 | OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING A MONOAMINOBENZENE AND A METAL CATALYST | L'OREAL (FR) | 2016-05-12 | — | — | US | disclosed |
| US-20160128922-A1 | OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING A MONOAMINOBENZENE AND A METAL CATALYST | L'OREAL (FR) | 2016-05-12 | — | — | US | disclosed |
| EP-1628666-B1 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | NEUROGENETIC PHARMACEUTICALS INC (US) | 2015-09-23 | — | — | EP | disclosed |
| EP-1628666-B1 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | NEUROGENETIC PHARMACEUTICALS INC (US) | 2015-09-23 | — | — | EP | disclosed |
| WO-2015042405-A1 | PH SWITCHABLE REAGENTS AND METHODS FOR THEIR USE | IMPOSSIBLE FOODS INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| WO-2014202787-A1 | OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING A MONOAMINOBENZENE AND A METAL CATALYST | L'OREAL (FR) | 2014-12-24 | — | — | WO | disclosed |
| US-8119680-B2 | α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119680-B2 | α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119680-B2 | α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20070249833-A1 | such as 2-bromo-1-[6-(4-methyl-imidazole-1-yl)-pyridin-3-yl]-ethanone, which have activity in modulating levels of amyloid-beta, useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease | TORREYPINES THERAPEUTICS INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249833-A1 | such as 2-bromo-1-[6-(4-methyl-imidazole-1-yl)-pyridin-3-yl]-ethanone, which have activity in modulating levels of amyloid-beta, useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease | TORREYPINES THERAPEUTICS INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249833-A1 | such as 2-bromo-1-[6-(4-methyl-imidazole-1-yl)-pyridin-3-yl]-ethanone, which have activity in modulating levels of amyloid-beta, useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease | TORREYPINES THERAPEUTICS INC. | 2007-10-25 | — | — | US | disclosed |
| US-7244739-B2 | Compounds and uses thereof in modulating amyloid beta | TORREYPINES THERAPEUTICS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244739-B2 | Compounds and uses thereof in modulating amyloid beta | TORREYPINES THERAPEUTICS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244739-B2 | Compounds and uses thereof in modulating amyloid beta | TORREYPINES THERAPEUTICS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1628666-A2 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | Torreypines Therapeutics, Inc. (US) | 2006-03-01 | — | — | EP | disclosed |
| US-20050070538-A1 | Compounds and uses thereof in modulating amyloid beta | SIROCCO THERAPEUTICS, INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2004110350-A2 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | TORREYPINES THERAPEUTICS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004110350-A2 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | TORREYPINES THERAPEUTICS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10251827-B2 | Oxidation dyeing process using a composition comprising a monoaminobenzene and a metal catalyst | KRT18, CYB5R3, CBR3 | ALDH1A1 444/4885MAPT 1029/4885HSD17B10 467/4885 |
| US-20050070538-A1 | Compounds and uses thereof in modulating amyloid beta | APP, BACE1, BACE2 | ALDH1A1 2224/4885MAPT 10/4885HSD17B10 1824/4885 |
| US-20160128922-A1 | OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING A MONOAMINOBENZENE AND A METAL CATALYST | KRT18, CYB5R3, CBR3 | ALDH1A1 441/4885MAPT 863/4885HSD17B10 409/4885 |
| US-20070249833-A1 | such as 2-bromo-1-[6-(4-methyl-imidazole-1-yl)-pyridin-3-yl]-ethanone, which have activity in modulating levels of amyloid-beta, useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease | PSEN2, APP, BACE1 | ALDH1A1 1789/4885MAPT 24/4885HSD17B10 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.